All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether distal splenorenal shunt changes all‐cause mortality compared with endoscopic intervention (very low certainty).
1 finding from 1 review
Rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether distal splenorenal shunt changes rebleeding compared with endoscopic intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality due to rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether distal splenorenal shunt changes mortality due to rebleeding compared with endoscopic intervention (very low certainty).
1 finding from 1 review
Acute hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether distal splenorenal shunt changes acute hepatic encephalopathy compared with endoscopic intervention (very low certainty).
1 finding from 1 review
Chronic hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether distal splenorenal shunt changes chronic hepatic encephalopathy compared with endoscopic intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether total shunt changes all‐cause mortality compared with endoscopic intervention (very low certainty).
1 finding from 1 review
Rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether total shunt changes rebleeding compared with endoscopic intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete miscarriage · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher complete miscarriage compared with placebo (low certainty).
1 finding from 1 review
Nausea · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher nausea compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Diarrhoea · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher diarrhoea compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher pain relief compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Woman’s satisfaction/acceptability of method · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Pelvic infection · early fetal death (less than 24 weeks)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nausea · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in nausea compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in diarrhoea compared with placebo (low certainty).
1 finding from 1 review
Blood loss: haemoglobin difference > 10 g/L · early fetal death (less than 24 weeks)
It is very uncertain whether vaginal misoprostol changes blood loss: haemoglobin difference > 10 g/L compared with placebo (very low certainty).
1 finding from 1 review
Opiate use (as a proxy measure for pain) for all participants on ITT (including those without confirmed AMI) · early fetal death (less than 24 weeks)
It is very uncertain whether vaginal misoprostol changes pain (opiate use) compared with placebo (very low certainty).
1 finding from 1 review
Woman’s satisfaction/acceptability of method · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with placebo (low certainty).
1 finding from 1 review